Skip to main content

Table 3 Demographics, risk factors for pneumonia, and SLE-specific data of European patients *

From: Influenza and pneumococcal vaccination coverage in Latin American patients with systemic lupus erythematosus: a cross-sectional and comparative study

 

Spain

(232)

Portugal

(184)

UK/Ireland

(151)

France

(82)

Italy

(59)

All patients

(744)**

Age, years (SD)

43 (11.1)

42,1 (10.1)

44.5 (11.6)

40,3 (11.2)

42.8 (10.1)

42.7 (11)

Female

220 (94.8)

179 (97.3)

144 (95.4)

79 (96.3)

56 (94.9)

711 (95.6)

Patients > 50 years

60 (25.9)

37 (20.1)

42 (27.8)

13 (15.9)

13 (22)

174 (23.4)

Disease duration, years (range)

10 (1–39)

10 (0–34)

9 (0.5–41)

5 (1–31)

10 (1–37)

9 (0–41)

Disease duration > 7 years

141 (60.8)

109 (59.2)

86 (57)

38 (46.3)

37 (62.7)

426 (57.2)

Immunosuppressors a

173 (74.6)

135 (73.4)

102 (67.5)

67 (81.7)

43 (72.9)

546 (73.4)

SLE activity b

119 (51.3)

94 (51.1)

88 (58.3)

45 (54.9)

30 (50.8)

395 (53.1)

Corticosteroid use c

70 (30.2)

81 (44)

40 (26.5)

26 (31.7)

23 (39)

249 (33.5)

Hydroxychloroquine

152 (65.5)

129 (70.1)

109 (72.2)

44 (53.7)

31 (52.5)

492 (66.1)

Smoking d

70 (30.2)

61 (33.2)

29 (19.2)

29 (35.4)

22 (37.3)

219 (29.4)

Chronic renal disease

42 (18.1)

16 (8.7)

17 (11.3)

8 (9.8)

14 (23.7)

104 (14)

Chronic respiratory disease

35 (15.1)

22 (12)

33 (21.9)

18 (22)

9 (15.3)

124 (16.7)

Chronic cardiac disease

22 (9.5)

18 (9.8)

8 (5.3)

4 (4.9)

6 (10.2)

64 (8.6)

Diabetes

6 (2.6)

6 (3.3)

3 (2.0)

2 (2.4)

2 (3.4)

20 (2.7)

> 1 risk factors for pneumonia e

172 (74.1)

140 (76.1)

113 (74.8)

57 (69.5)

47 (79.7)

556 (74.7)

  1. * Except where indicated otherwise, values are the number (%) of patients. SD: Standard deviation, SLE: Systemic Lupus Erythematosus
  2. ** Other participating countries: Belgium (12 patients), Netherlands (6 patients), Luxembourg (4 patients), Denmark (3 patients), Germany (2 patients), Greece (2 patients), Switzerland (2 patients), Andorra (1 patient), Croatia (1 patient), Cyprus (1 patient), Iceland (1 patient), Norway (1 patient)
  3. aNot including corticosteroids and hydroxychloroquine
  4. bSLE activity was defined as the presence of flares-up diagnosed by a doctor during the previous 6 months
  5. cCorticosteroid use was defined as use of prednisone ≥7.5 mg daily or equivalent during the last month
  6. dSmoking was defined as currently smoking or having quit < 6 months ago
  7. eRisk factors for pneumonia assessed were: age > 50 years, diabetes, current use of immunosuppressors, daily dose of prednisone > 7.5 mg or equivalent during the last month, SLE activity, and the coexistence of chronic cardiac, respiratory or renal disease
Back to article page

Advances in Rheumatology

ISSN: 2523-3106